Cause-specific hazards of relapse in the 213 patients with CR
| . | No. of patients . | No. of relapses . | Univariable analysis (213 patients, 54 relapses) . | Multivariable analysis (191 patients, 46 events) . | ||||
|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |||
| Age, y | 213 | — | 1.02 | (0.96-1.08) | .51 | — | — | — |
| Sex | ||||||||
| Female | 37 | 4 | Ref | — | — | — | — | — |
| Male | 176 | 50 | 2.98 | (1.08-8.25) | .036 | — | — | — |
| CNS involvement | ||||||||
| No | 197 | 51 | Ref | — | — | — | — | — |
| Yes | 16 | 3 | 0.62 | (0.19-2) | .42 | — | — | — |
| WBC count, ×109/L | ||||||||
| <200 | 162 | 36 | Ref | — | — | — | — | — |
| ≥200 | 51 | 18 | 1.93 | (1.1-3.4) | .023 | 1.85 | (1.01-3.37) | .0456 |
| Day 21 CHr | ||||||||
| Yes | 184 | 42 | Ref | — | — | — | — | — |
| No | 26 | 12 | 2.43 | (1.28-4.61) | .007 | — | — | — |
| Oncogenetics | ||||||||
| gLoR | 109 | 15 | Ref | |||||
| gHiR | 104 | 39 | 3.49 | (1.92-6.34) | <.0001 | 3.22 | (1.64-6.28) | .0006 |
| MRD | ||||||||
| <10−4 | 114 | 18 | Ref | — | — | — | — | — |
| ≥10−4 | 77 | 28 | 2.84 | (1.57-5.15) | .0006 | 2.30 | (1.20-4.02) | .0007 |
| . | No. of patients . | No. of relapses . | Univariable analysis (213 patients, 54 relapses) . | Multivariable analysis (191 patients, 46 events) . | ||||
|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |||
| Age, y | 213 | — | 1.02 | (0.96-1.08) | .51 | — | — | — |
| Sex | ||||||||
| Female | 37 | 4 | Ref | — | — | — | — | — |
| Male | 176 | 50 | 2.98 | (1.08-8.25) | .036 | — | — | — |
| CNS involvement | ||||||||
| No | 197 | 51 | Ref | — | — | — | — | — |
| Yes | 16 | 3 | 0.62 | (0.19-2) | .42 | — | — | — |
| WBC count, ×109/L | ||||||||
| <200 | 162 | 36 | Ref | — | — | — | — | — |
| ≥200 | 51 | 18 | 1.93 | (1.1-3.4) | .023 | 1.85 | (1.01-3.37) | .0456 |
| Day 21 CHr | ||||||||
| Yes | 184 | 42 | Ref | — | — | — | — | — |
| No | 26 | 12 | 2.43 | (1.28-4.61) | .007 | — | — | — |
| Oncogenetics | ||||||||
| gLoR | 109 | 15 | Ref | |||||
| gHiR | 104 | 39 | 3.49 | (1.92-6.34) | <.0001 | 3.22 | (1.64-6.28) | .0006 |
| MRD | ||||||||
| <10−4 | 114 | 18 | Ref | — | — | — | — | — |
| ≥10−4 | 77 | 28 | 2.84 | (1.57-5.15) | .0006 | 2.30 | (1.20-4.02) | .0007 |
CHr, chemoresistance (defined by blasts >5% in bone marrow); CNS, central nervous system; Ref, reference.